» Articles » PMID: 37112668

Developments in Rabies Vaccines: The Path Traversed from Pasteur to the Modern Era of Immunization

Overview
Date 2023 Apr 28
PMID 37112668
Authors
Affiliations
Soon will be listed here.
Abstract

Rabies is a disease of antiquity and has a history spanning millennia ever since the first interactions between humans and dogs. The alarming fatalities caused by this disease have triggered rabies prevention strategies since the first century BC. There have been numerous attempts over the past 100 years to develop rabies vaccineswith the goal of preventing rabies in both humans and animals. Thepre-Pasteurian vaccinologists, paved the way for the actual history of rabies vaccines with the development of first generation vaccines. Further improvements for less reactive and more immunogenic vaccines have led to the expansion of embryo vaccines, tissue culture vaccines, cell culture vaccines, modified live vaccines, inactivated vaccines, and adjuvanted vaccines. The adventof recombinant technology and reverse genetics have given insight into the rabies viral genome and facilitated genome manipulations, which in turn led to the emergence of next-generation rabies vaccines, such as recombinant vaccines, viral vector vaccines, genetically modified vaccines, and nucleic acid vaccines. These vaccines were very helpful in overcoming the drawbacks of conventional rabies vaccines with increased immunogenicity and clinical efficacies. The path traversed in the development of rabies vaccines from Pasteur to the modern era vaccines, though, faced numerous challenges;these pioneering works have formed the cornerstone for the generation of thecurrent successful vaccines to prevent rabies. In the future, advancements in the scientific technologies and research focus will definitely lay the path for much more sophisticated vaccine candidates for rabies elimination.

Citing Articles

Optimizing rabies mRNA vaccine efficacy via RABV-G structural domain screening and heterologous prime-boost immunization.

Li D, Wang X, Li G, Zhou J, Bian L, Zhao X NPJ Vaccines. 2025; 10(1):43.

PMID: 40025078 PMC: 11873297. DOI: 10.1038/s41541-025-01098-w.


A prospective study on safety and clinical efficacy of rabies biologicals in paediatric patients with category III animal exposure.

Fotedar N, Ravish H Clin Exp Vaccine Res. 2025; 14(1):59-66.

PMID: 39927229 PMC: 11799581. DOI: 10.7774/cevr.2025.14.e1.


Epidemiology, transmission dynamics, risk factors, and future directions of rabies in the Arabian Peninsula using one health approach: a review.

Islam M, Naeem A, Mshelbwala P, Dutta P, Hassan M, K Elfadl A Eur J Public Health. 2025; 35(Supplement_1):i14-i22.

PMID: 39801328 PMC: 11725953. DOI: 10.1093/eurpub/ckae164.


Deep mutational scanning of rabies glycoprotein defines mutational constraint and antibody-escape mutations.

Aditham A, Radford C, Carr C, Jasti N, King N, Bloom J bioRxiv. 2025; .

PMID: 39763725 PMC: 11702696. DOI: 10.1101/2024.12.17.628970.


A nucleoside-modified rabies mRNA vaccine induces long-lasting and comprehensive immune responses in mice and non-human primates.

Wang Y, Wang S, Haung L, Huang L, Mao W, Li F Mol Ther. 2025; 33(2):548-559.

PMID: 39741409 PMC: 11853375. DOI: 10.1016/j.ymthe.2024.12.041.


References
1.
Bonito R, de Oliveira N, Nishioka S . Adverse reactions associated with a Fuenzalida-Palacios rabies vaccine: a quasi-experimental study. Rev Soc Bras Med Trop. 2004; 37(1):7-9. DOI: 10.1590/s0037-86822004000100002. View

2.
Olayan E, El-Khadragy M, Mohamed A, Mohamed A, Shebl R, Yehia H . Evaluation of Different Stabilizers and Inactivating Compounds for the Enhancement of Vero Cell Rabies Vaccine Stability and Immunogenicity: Study. Biomed Res Int. 2019; 2019:4518163. PMC: 6441502. DOI: 10.1155/2019/4518163. View

3.
Freuling C, Hampson K, Selhorst T, Schroder R, Meslin F, Mettenleiter T . The elimination of fox rabies from Europe: determinants of success and lessons for the future. Philos Trans R Soc Lond B Biol Sci. 2013; 368(1623):20120142. PMC: 3720040. DOI: 10.1098/rstb.2012.0142. View

4.
Lodmell D, Ewalt L . Post-exposure DNA vaccination protects mice against rabies virus. Vaccine. 2001; 19(17-19):2468-73. DOI: 10.1016/s0264-410x(00)00475-8. View

5.
Shuai L, Feng N, Wang X, Ge J, Wen Z, Chen W . Genetically modified rabies virus ERA strain is safe and induces long-lasting protective immune response in dogs after oral vaccination. Antiviral Res. 2015; 121:9-15. DOI: 10.1016/j.antiviral.2015.06.011. View